{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T19:48:17Z","timestamp":1772308097919,"version":"3.50.1"},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:p>In utero fetal therapy offers the opportunity to prevent and treat diseases with a cellular or genetic basis. Components of successful fetal treatment include isolation of a replacement cell population, in utero stem cell transplantation, cell engraftment with fetal immune tolerance, and ongoing cell function. Fetal gene therapy with CRISPR-Cas9 represents an exciting potential therapy for genetic diseases not amenable to gene supplementation via adenoviral vector transduction. These fetal therapies have unique ethical and safety considerations. Clinical trials for in utero cell therapy are underway, as additional discoveries in stem cell biology and gene therapy move closer to clinical translation.<\/jats:p>","DOI":"10.1097\/grf.0000000000000663","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T20:01:49Z","timestamp":1634760109000},"page":"861-875","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["In Utero Fetal Therapy: Stem Cells, Cell Transplantation, Gene Therapy, and CRISPR-Cas9"],"prefix":"10.1097","volume":"64","author":[{"given":"Matthew A.","family":"Shear","sequence":"first","affiliation":[{"name":"Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Massa","sequence":"additional","affiliation":[{"name":"Columbia Vagelos College of Physicians and Surgeons, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"key":"R1-20250512","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11914-020-00594-3","article-title":"Stem cell therapy as a treatment for osteogenesis imperfecta","volume":"18","author":"G\u00f6therstr\u00f6m","year":"2020","journal-title":"Curr Osteoporos Rep"},{"key":"R2-20250512","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s40778-018-0119-7","article-title":"In utero hematopoietic cell transplantation: past clinical experience and future clinical trials","volume":"4","author":"Witt","year":"2018","journal-title":"Curr Stem Cell Rep"},{"key":"R3-20250512","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40778-019-00165-y","article-title":"Mechanistic insights into factor VIII immune tolerance induction via prenatal cell therapy in hemophilia A","volume":"5","author":"Rodriguez","year":"2019","journal-title":"Curr Stem Cell Rep"},{"key":"R4-20250512","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nprot.2012.157","article-title":"Derivation of human embryonic stem cells using a post-inner cell mass intermediate","volume":"8","author":"O\u2019Leary","year":"2013","journal-title":"Nat Protoc"},{"key":"R5-20250512","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cell.2014.09.040","article-title":"Generation of functional human pancreatic \u03b2 cells in vitro","volume":"159","author":"Pagliuca","year":"2014","journal-title":"Cell"},{"key":"R6-20250512","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/bs.ctdb.2015.10.005","article-title":"Cell fate determination by transcription factors","volume":"116","author":"Gurdon","year":"2016","journal-title":"Curr Top Dev Biol"},{"key":"R7-20250512","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"R8-20250512","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41536-019-0083-6","article-title":"Mesenchymal stem cell perspective: cell biology to clinical progress","volume":"4","author":"Pittenger","year":"2019","journal-title":"NPJ Regen Med"},{"key":"R9-20250512","doi-asserted-by":"crossref","first-page":"e0136199","DOI":"10.1371\/journal.pone.0136199","article-title":"Single-cell RNA-Seq of bone marrow-derived mesenchymal stem cells reveals unique profiles of lineage priming","volume":"10","author":"Freeman","year":"2015","journal-title":"PLoS One"},{"key":"R10-20250512","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13287-017-0483-8","article-title":"Systematic review of patient factors affecting adipose stem cell viability and function: implications for regenerative therapy","volume":"8","author":"Varghese","year":"2017","journal-title":"Stem Cell Res Ther"},{"key":"R11-20250512","first-page":"485","article-title":"Three-dimensional culture systems to induce chondrogenesis of adipose-derived stem cells","volume":"702","author":"Estes","year":"2011","journal-title":"Methods Mol Biol"},{"key":"R12-20250512","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.stem.2008.07.003","article-title":"A perivascular origin for mesenchymal stem cells in multiple human organs","volume":"3","author":"Crisan","year":"2008","journal-title":"Cell Stem Cell"},{"key":"R13-20250512","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1073\/pnas.0937635100","article-title":"SHED: stem cells from human exfoliated deciduous teeth","volume":"100","author":"Miura","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"R14-20250512","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-38275-y","article-title":"Therapeutic potential of hepatocyte-like-cells converted from stem cells from human exfoliated deciduous teeth in fulminant Wilson\u2019s disease","volume":"9","author":"Fujiyoshi","year":"2019","journal-title":"Sci Rep"},{"key":"R15-20250512","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1634\/stemcells.2004-0058","article-title":"Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta","volume":"22","author":"In\u2019t Anker","year":"2004","journal-title":"Stem Cells"},{"key":"R16-20250512","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1634\/stemcells.21-1-105","article-title":"Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord","volume":"21","author":"Romanov","year":"2003","journal-title":"Stem Cells"},{"key":"R17-20250512","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1634\/stemcells.2005-0271","article-title":"Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases","volume":"24","author":"Son","year":"2006","journal-title":"Stem Cells"},{"key":"R18-20250512","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1038\/cddis.2013.304","article-title":"Mesenchymal stromal-cell transplants induce oligodendrocyte progenitor migration and remyelination in a chronic demyelination model","volume":"4","author":"Jaramillo-Merch\u00e1n","year":"2013","journal-title":"Cell Death Dis"},{"key":"R19-20250512","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.4161\/cc.8.7.8121","article-title":"Differentiation of human fetal mesenchymal stem cells into cells with an oligodendrocyte phenotype","volume":"8","author":"Kennea","year":"2009","journal-title":"Cell Cycle"},{"key":"R20-20250512","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10815-017-1038-8","article-title":"Earlier day of blastocyst development is predictive of embryonic euploidy across all ages: essential data for physician decision-making and counseling patients","volume":"35","author":"Kaing","year":"2018","journal-title":"J Assist Reprod Genet"},{"key":"R21-20250512","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2004-04-1559","article-title":"Human mesenchymal stem cells modulate allogeneic immune cell responses","volume":"105","author":"Aggarwal","year":"2005","journal-title":"Blood"},{"key":"R22-20250512","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"R23-20250512","first-page":"2396","article-title":"Identification of mesenchymal stem cells in human first trimester fetal blood, liver and bone marrow","volume":"96","author":"Carapagnoli","year":"2000","journal-title":"Blood"},{"key":"R24-20250512","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.ymthe.2020.10.012","article-title":"Fetal and maternal safety considerations for in utero therapy clinical trials: iFeTiS consensus statement","volume":"28","author":"Sagar","year":"2020","journal-title":"Mol Ther"},{"key":"R25-20250512","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40778-018-0118-8","article-title":"Fetal mesenchymal stromal cells: an opportunity for prenatal cellular therapy","volume":"4","author":"Sagar","year":"2018","journal-title":"Curr Stem Cell Rep"},{"key":"R26-20250512","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1634\/stemcells.2006-0208","article-title":"Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC","volume":"25","author":"Guillot","year":"2007","journal-title":"Stem Cells"},{"key":"R27-20250512","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1093\/humrep\/den302","article-title":"First trimester embryo-fetoscopic and ultrasound-guided fetal blood sampling for ex vivo viral transduction of cultured human fetal mesenchymal stem cells","volume":"23","author":"Chan","year":"2008","journal-title":"Hum Reprod"},{"key":"R28-20250512","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2015.00015","article-title":"Consensus statement from the first international conference for in utero stem cell transplantation and gene therapy","volume":"6","author":"MacKenzie","year":"2015","journal-title":"Front Pharmacol"},{"key":"R29-20250512","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jpedsurg.2015.10.059","article-title":"Fetal surgical conditions and the unraveling of maternal\u2013fetal tolerance","volume":"51","author":"MacKenzie","year":"2016","journal-title":"J Pediatr Surg"},{"key":"R30-20250512","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1126\/science.1164511","article-title":"Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero","volume":"322","author":"Mold","year":"2008","journal-title":"Science"},{"key":"R31-20250512","doi-asserted-by":"crossref","first-page":"325.e1","DOI":"10.1016\/j.ajog.2007.09.047","article-title":"Maternal microchimerism in human fetal tissues","volume":"198","author":"Jonsson","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"R32-20250512","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/labinvest.3700471","article-title":"Maternal microchimerism in healthy adults in lymphocytes, monocyte\/macrophages and NK cells","volume":"86","author":"Loubi\u00e8re","year":"2006","journal-title":"Lab Invest"},{"key":"R33-20250512","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1073\/pnas.0606169104","article-title":"Maternal microchimerism in peripheral blood in type 1 diabetes and pancreatic islet cell microchimerism","volume":"104","author":"Nelson","year":"2007","journal-title":"PNAS"},{"key":"R34-20250512","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(03)14795-2","article-title":"Myocardial-tissue-specific phenotype of maternal microchimerism in neonatal lupus congenital heart block","volume":"362","author":"Stevens","year":"2003","journal-title":"Lancet"},{"key":"R35-20250512","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1600-6143.2011.03895.x","article-title":"Decreased risk of graft failure with maternal liver transplantation in patients with biliary atresia: less graft failure with maternal livers","volume":"12","author":"Nijagal","year":"2012","journal-title":"Am J Transplant"},{"key":"R36-20250512","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1210\/er.2008-0031","article-title":"Ethical issues in stem cell research","volume":"30","author":"Lo","year":"2009","journal-title":"Endocr Rev"},{"issue":"C","key":"R37-20250512","doi-asserted-by":"crossref","first-page":"16020","DOI":"10.1038\/mtm.2016.20","article-title":"In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application","volume":"5","author":"Almeida-Porada","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"R38-20250512","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.cell.2021.02.036","article-title":"Heritable human genome editing: research progress, ethical considerations, and hurdles to clinical practice","volume":"184","author":"Turocy","year":"2021","journal-title":"Cell"},{"key":"R39-20250512","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ymthe.2019.02.015","article-title":"In utero gene therapy consensus statement from the IFeTIS","volume":"27","author":"Almeida-Porada","year":"2019","journal-title":"Mol Ther"},{"key":"R41-20250512","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1089\/hum.2017.038","article-title":"Adeno-associated virus vectors and stem cells: friends or foes?","volume":"28","author":"Brown","year":"2017","journal-title":"Hum Gene Ther"},{"key":"R42-20250512","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.ymthe.2017.05.005","article-title":"Codon-optimized RPGR improves stability and efficacy of AAV8 gene therapy in two mouse models of X-linked retinitis pigmentosa","volume":"25","author":"Fischer","year":"2017","journal-title":"Mol Ther"},{"key":"R43-20250512","first-page":"1760","article-title":"Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential","volume":"14","author":"Li","year":"2008","journal-title":"Mol Vis"},{"key":"R44-20250512","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1167\/tvst.9.3.17","article-title":"Perspectives on gene therapy: choroideremia represents a challenging model for the treatment of other inherited retinal degenerations","volume":"9","author":"MacDonald","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"R45-20250512","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1016\/j.ymthe.2017.08.018","article-title":"AAV8 can induce innate and adaptive immune response in the primate eye","volume":"25","author":"Reichel","year":"2017","journal-title":"Mol Ther"},{"key":"R46-20250512","doi-asserted-by":"crossref","first-page":"189ra76","DOI":"10.1126\/scitranslmed.3005708","article-title":"In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci Transl Med"},{"key":"R47-20250512","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/gt.2008.66","article-title":"AAV-mediated gene therapy for retinal disorders: from mouse to man","volume":"15","author":"Buch","year":"2008","journal-title":"Gene Ther"},{"key":"R48-20250512","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.mt.6300123","article-title":"Immune responses to AAV capsid: are mice not humans after all?","volume":"15","author":"Herzog","year":"2007","journal-title":"Mol Ther"},{"key":"R49-20250512","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human immune responses to adeno-associated virus (AAV) vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front Immunol"},{"key":"R50-20250512","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8+ T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"},{"key":"R51-20250512","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.mt.6300090","article-title":"Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate aav-transduced hepatocytes","volume":"15","author":"Li","year":"2007","journal-title":"Mol Ther"},{"key":"R52-20250512","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2012-10-460733","article-title":"Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells","volume":"121","author":"Martino","year":"2013","journal-title":"Blood"},{"key":"R53-20250512","doi-asserted-by":"crossref","first-page":"6940283","DOI":"10.1155\/2016\/6940283","article-title":"Stem cells applications in regenerative medicine and disease therapeutics","volume":"2016","author":"Mahla","year":"2016","journal-title":"Int J Cell Biol"},{"key":"R54-20250512","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/ICU.0b013e328352407d","article-title":"Stem cell therapy for retinal disease","volume":"23","author":"Tibbetts","year":"2012","journal-title":"Curr Opin Ophthalmol"},{"key":"R55-20250512","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.ymthe.2017.05.015","article-title":"Using CRISPR-Cas9 to generate gene-corrected autologous iPSCs for the treatment of inherited retinal degeneration","volume":"25","author":"Burnight","year":"2017","journal-title":"Mol Ther"},{"key":"R56-20250512","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-1-4939-7522-8_10","article-title":"AAV gene augmentation therapy for CRB1-associated retinitis pigmentosa","volume":"1715","author":"Alves","year":"2018","journal-title":"Methods Mol Biol"},{"key":"R57-20250512","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3390\/genes8090232","article-title":"Effects of cellular methylation on transgene expression and site-specific integration of adeno-associated virus","volume":"8","author":"Chanda","year":"2017","journal-title":"Genes"},{"key":"R58-20250512","first-page":"443","article-title":"CRISPR therapeutic tools for complex genetic disorders and cancer (review)","volume":"53","author":"Baliou","year":"2018","journal-title":"Int J Oncol"},{"key":"R59-20250512","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1042\/BCJ20170793","article-title":"CRISPR base editors: genome editing without double-stranded breaks","volume":"475","author":"Eid","year":"2018","journal-title":"Biochem J"},{"key":"R60-20250512","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.3390\/ijms21176240","article-title":"CRISPR-Cas9 DNA base-editing and prime-editing","volume":"21","author":"Kantor","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R61-20250512","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat Protoc"},{"key":"R62-20250512","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/biot.201400046","article-title":"CRISPR\/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox","volume":"9","author":"Sen\u00eds","year":"2014","journal-title":"Biotechnol J"},{"key":"R63-20250512","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/APO.0000000000000225","article-title":"Clustered regularly interspaced short palindromic repeats: challenges in treating retinal disease","volume":"5","author":"Chrenek","year":"2016","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R64-20250512","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41551-019-0501-5","article-title":"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses","volume":"4","author":"Levy","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"R65-20250512","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nat Lond"},{"key":"R66-20250512","article-title":"Prime editing primarily induces undesired outcomes in mice","author":"Aida","year":"2020","journal-title":"Mol Biol"}],"container-title":["Clinical Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000663","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T15:11:26Z","timestamp":1747062686000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/grf.0000000000000663","relation":{},"ISSN":["0009-9201"],"issn-type":[{"value":"0009-9201","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,21]]}}}